Imprimis NJOF, LLC recalls Tri-Moxi+¿
- Recalling company
- Imprimis NJOF, LLC
- Product
- Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
- Reason
- Presence of particulate matter - Glass like particles.
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Dec 18, 2025
- Reported
- Jan 14, 2026
- Distribution
- U.S Nationwide
- Status
- Ongoing
- Quantity
- 314 boxes of 6,280 pre-filled syringes
- Lot / codes
- Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
- Company location
- Ledgewood, NJ
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0251-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0251-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.